Oruka Therapeutics, Inc. (ORKA) Week 28 Psoriasis Data: PASI 100 71.4%
Oruka Therapeutics reported EVERLAST-A Week 28 data for ORKA-001: PASI 100 rose to 71.4% and PASI 90 to 87.3% without dosing after Week 4; safety remained consistent with IL-23 class. Placebo crossovers showed similar response patterns. 52-week data expected Dec 2026.Material DetailsContext by AI A…